Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12901253 | 0.83 | CA12 (0.35) | CHRM2 | |
| SCHEMBL18713493 | 0.81 | — | — | |
| SCHEMBL18595101 | 0.81 | — | — | |
| SCHEMBL7193560 | 0.79 | — | — | |
| SCHEMBL15120327 | 0.76 | PRMT3 (0.32) | — | |
| SCHEMBL22756766 | 0.71 | — | — | |
| SCHEMBL6966966 | 0.69 | — | — | |
| SCHEMBL13915185 | 0.67 | CHRM2 (0.57) | CHRM2 | |
| SCHEMBL1702199 | 0.67 | CA12 (0.38) | — | |
| SCHEMBL16131175 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772413-B2 | Amide and peptide derivatives of tetraalkylenepentamines as transfection agents | GLAXO GROUP LIMITED (GB) | 2010-08-10 | — | — | US | disclosed |
| US-20090149401-A1 | AMIDE AND PEPTIDE DERIVATIVES OF TETRAALKYLENEPENTAMINES AS TRANSFECTION AGENTS | GLAXO GROUP LIMITED (GB) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149401-A1 | AMIDE AND PEPTIDE DERIVATIVES OF TETRAALKYLENEPENTAMINES AS TRANSFECTION AGENTS | PCTP, PHOSPHO1, PLTP | CHRM2 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.